Although drug spend is increasing for inflammatory conditions, diabetes, and oncology, there are some promising developments in the pipeline.
Erin Bastick, PharmD, RPh
New updates in insulin products, as well as non-pharma therapies are on the horizon for diabetes.
New treatment indications are under investigation for the use of cannabinoid-based drugs.
Experts share updates on new diabetes medications, and provide an overview of what’s coming.